{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mangoni AA"],"funding":["Tour de Cure Research, Support, and Prevention, Senior Research Grant"],"pagination":["1017"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8840040"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(3)"],"pubmed_abstract":["The pharmacokinetic profile of ZST316 and ZST152, arginine analogues with inhibitory activity towards human dimethylarginine dimethylaminohydrolase-1 (DDAH1), was investigated in mice using a newly developed HPLC-MS/MS method. The method proved to be reproducible, precise, and accurate for the measurement of the compounds in plasma and urine. Four-week-old female FVB mice received a single dose of ZST316 and ZST152 by intravenous bolus (30 mg/Kg) and oral gavage (60 mg/Kg). ZST316 Cmax was 67.4 µg/mL (intravenous) and 1.02 µg/mL (oral), with a half-life of 6 h and bioavailability of 4.7%. ZST152 Cmax was 24.9 µg/mL (intravenous) and 1.65 µg/mL (oral), with a half-life of 1.2 h and bioavailability of 33.3%. Urinary excretion of ZST152 and ZST316 was 12.5%-22.2% and 2.3%-7.5%, respectively. "],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method."],"pmcid":["PMC8840040"],"funding_grant_id":["RSP-246-18/19"],"pubmed_authors":["Mangoni AA","Zucchetti M","Tommasi S","Fichera S","Russo M","Ceruti T","Frapolli R"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method.","description":"The pharmacokinetic profile of ZST316 and ZST152, arginine analogues with inhibitory activity towards human dimethylarginine dimethylaminohydrolase-1 (DDAH1), was investigated in mice using a newly developed HPLC-MS/MS method. The method proved to be reproducible, precise, and accurate for the measurement of the compounds in plasma and urine. Four-week-old female FVB mice received a single dose of ZST316 and ZST152 by intravenous bolus (30 mg/Kg) and oral gavage (60 mg/Kg). ZST316 Cmax was 67.4 µg/mL (intravenous) and 1.02 µg/mL (oral), with a half-life of 6 h and bioavailability of 4.7%. ZST152 Cmax was 24.9 µg/mL (intravenous) and 1.65 µg/mL (oral), with a half-life of 1.2 h and bioavailability of 33.3%. Urinary excretion of ZST152 and ZST316 was 12.5%-22.2% and 2.3%-7.5%, respectively. ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-25T23:01:30.112Z","creation":"2025-04-06T09:13:41.239Z"},"accession":"S-EPMC8840040","cross_references":{"pubmed":["35164277"],"doi":["10.3390/molecules27031017"]}}